← Back to codex

Urolithin A

Aliases: Mitopure

Last verified: 2026-09-23

Approved drugModerate evidenceSmall moleculesMedium interest

The short version

A pomegranate postbiotic (the microbiome makes it from ellagitannins) — activates mitophagy, mitochondrial "recycling". RCT evidence: improved muscle endurance and strength in the elderly.

Identity & type

Molecular type
mali molekul
Origin
A pomegranate postbiotic (the microbiome makes it from ellagitannins) — activates mitophagy, mitochondrial "recycling".

Mechanism of action

Mitophagy induction → clearance of damaged mitochondria → better cellular energetics.

Dosing & routes

Official / clinical context

Approved drug — indications, dosing and warnings are defined by the official label. 500–1000 mg/day (studied doses).

Regulator-approved labeling and published study designs — never a recommendation.

Community-reported practice

500–1000 mg/day (studied doses). Mitopure users report better muscle endurance and less fatigue after 4–8 weeks; effects modest but consistent in trials.

Unverified self-reports. Not medical advice. Not endorsement.

Expected effects (community)

Mitopure users report better muscle endurance and less fatigue after 4–8 weeks; effects modest but consistent in trials.

Protocol — official vs community

Official / label

Supplement (Mitopure). RCTs used 500–1,000 mg daily (muscle endurance, mitochondrial biomarkers).

  1. 01500–1,000 mg daily

Duration: Continuous; trial data at 4 months.

One of the few 'longevity supplements' with branded RCT data — modest but real.

Community (anecdotal)

500–1,000 mg daily.

Cycle:
Continuous.
Break:
None.

Pomegranate-eating gets you nothing if your microbiome doesn't convert it — that's the actual reason the purified form exists.

Human evidence

RCTs (Nature Metabolism 2022; JAMA 2022): +12% muscle endurance, improved mitochondrial markers.

Preclinical evidence

The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.

Known risks

  • Excellent tolerability.characterized

Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.

Unknowns & evidence gaps

  • Long-term safety in off-label use

Frequently asked questions

References